Association of Steroid 5α-Reductase Type 3 Congenital Disorder of Glycosylation With Early-Onset Retinal Dystrophy

Authors:

Abstract
Congenital disorders of glycosylation (CDGs) are a large group of neurometabolic diseases caused by impaired glycoconjugate synthesis. Type I CDGs (CDG-I) result from disruptions in the early N-linked glycosylation pathway.1 Numerous CDG-I subtypes exist that are characterized by neurologic, developmental, hepatic, and coagulation abnormalities alongside ocular, muscular, skeletal, dermatologic, cardiovascular, or genitourinary involvement in some forms.1,2 Approximately 23 different genes have been associated with this group of disorders.1 Steroid 5α-reductase type 3 (SRD5A3 [OMIM 611715]) encodes a polyprenol reductase enzyme required for the synthesis of dolichol, the end product of the mevalonate pathway.3 Dolichol undergoes phosphorylation to produce dolichol phosphate that serves as the lipid-anchor for N-glycan biosynthesis in the endoplasmic reticulum.3

This publication has 25 references indexed in Scilit: